Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Certain peptides may interact with blood pressure medications or affect blood sugar levels in diabetic patients
International Regulatory Landscape Healthcare Provider Considerations Healthcare providers who prescribe or recommend BPC-157 face potential: Disciplinary action from state medical boards Medical license implications (sanctions, restrictions, suspension) Malpractice liability (insurance often excludes experimental treatments) Federal regulatory enforcement Research and Access Legitimate research pathways: Investigational New Drug (IND) application required for human research Institutional Review Board (IRB) approval required GMP standards required for research-grade materials Current access: Research peptide suppliers (variable quality) Some compounding pharmacies (legal status varies) Clinical trials (limited availability) Why This Regulatory Status Exists BPC-157's prohibition stems from: Limited clinical data Only small pilot studies published (~28 human subjects total)
In Tech Open, London, UK, pp 241258
& Johnson, A
The cytosolic GSTs are profusely present and have been divided into divergent classes based on their genesis, catalytic amino-acid residue, sequence similarity, and substrate specificity (Labrou et al., 2015)
